Gupta Romi, Forloni Matteo, Bisserier Malik, Dogra Shaillay Kumar, Yang Qiaohong, Wajapeyee Narendra
Department of Pathology, Yale University School of Medicine, New Haven, United States.
Singapore Institute of Clinical Sciences, Agency for Science Technology and Research (A*STAR), Brenner Center for Molecular Medicine, Singapore, Singapore.
Elife. 2016 Sep 8;5:e16432. doi: 10.7554/eLife.16432.
Mutations in the oncogene are present in up to 20% of melanoma. Here, we show that interferon alpha-inducible protein 6 (IFI6) is necessary for NRASQ61K-induced transformation and melanoma growth. was transcriptionally upregulated by NRASQ61K, and knockdown of resulted in DNA replication stress due to dysregulated DNA replication via E2F2. This stress consequentially inhibited cellular transformation and melanoma growth via senescence or apoptosis induction depending on the RB and p53 pathway status of the cells. NRAS-mutant melanoma were significantly more resistant to the cytotoxic effects of DNA replication stress-inducing drugs, and knockdown of increased sensitivity to these drugs. Pharmacological inhibition of expression by the MEK inhibitor trametinib, when combined with DNA replication stress-inducing drugs, blocked NRAS-mutant melanoma growth. Collectively, we demonstrate that IFI6, via E2F2 regulates DNA replication and melanoma development and growth, and this pathway can be pharmacologically targeted to inhibit NRAS-mutant melanoma.
致癌基因中的突变存在于高达20%的黑色素瘤中。在此,我们表明干扰素α诱导蛋白6(IFI6)对于NRASQ61K诱导的转化和黑色素瘤生长是必需的。IFI6被NRASQ61K转录上调,敲低IFI6会由于通过E2F2导致DNA复制失调而引起DNA复制应激。这种应激继而根据细胞的RB和p53途径状态通过诱导衰老或凋亡来抑制细胞转化和黑色素瘤生长。NRAS突变的黑色素瘤对DNA复制应激诱导药物的细胞毒性作用明显更具抗性,敲低IFI6会增加对这些药物的敏感性。当MEK抑制剂曲美替尼与DNA复制应激诱导药物联合使用时,对IFI6表达的药理学抑制会阻断NRAS突变的黑色素瘤生长。总体而言,我们证明IFI6通过E2F2调节DNA复制以及黑色素瘤的发生和生长,并且该途径可通过药理学方法靶向抑制NRAS突变的黑色素瘤。